Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
AMG 133 is an investigational therapeutic agent being developed by Amgen for the treatment of obesity. It is a dual agonist monoclonal antibody targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). This innovative compound aims to enhance metabolic regulation by both promoting satiety and modulating glucose metabolism. AMG 133 is administered via subcutaneous injection and is currently under clinical evaluation for its efficacy and safety in reducing body weight in adults with obesity, with or without type 2 diabetes.
| Fact Table | |
| Formula | Not publicly disclosed (Peptide-based) |
| License | Investigational (Not FDA-approved) |
| Bioavailability | Not available |
| Legal status | Investigational |
| Chemical Name | AMG 133 (GLP-1 receptor agonist and GIP receptor antagonist) |
| Elimination half-life | ~ 6–7 days (based on Phase 1 data) |
| Dosage (Strength) | 140 mg, 280 mg (in clinical trials) |
| Pregnancy | Not established – use in clinical trials only |
| Brands | Not branded (Investigational) |
| Protein binding | Not reported |
| PubChem CID | Not assigned |
| MedlinePlus | Not listed |
| ChEBI | Not listed |
| ATC code | None assigned |
| DrugBank | Not assigned |
| KEGG | Not listed |
| Routes of administration | Subcutaneous injection |
As AMG 133 is currently an investigational product, dosing regimens are determined by clinical trial protocols. In ongoing studies, AMG 133 is typically administered once every four weeks via subcutaneous injection. All dosing should be guided by a healthcare professional within a controlled clinical trial or expanded access program until regulatory approval is obtained.
AMG 133 consists of a human monoclonal antibody engineered to function as a dual GIPR antagonist and GLP-1R agonist. Full excipient information is pending publication upon advancement to later-phase trials or approval.
As AMG 133 is still undergoing clinical testing, no formal contraindications have been established. However, patients with a history of hypersensitivity to monoclonal antibodies or active pancreatitis are generally excluded from trials and may be at higher risk of adverse reactions.
Use of AMG 133 is currently limited to clinical trial settings. Patients should be monitored for gastrointestinal symptoms, changes in glucose levels, and signs of hypersensitivity. The long-term cardiovascular and metabolic effects are still under investigation. Caution is advised in individuals with a history of pancreatitis, thyroid tumors, or severe gastrointestinal disease.
Based on Phase 1 trial data, potential side effects include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews